TLR9 and neoplasm: Similar phenomena were reported for other immunotherapy strategies; for example, CpGs which act as TLR-9 agonists, show increased potency when delivered by a nanoparticle, and this has been attributed to prolonged tumor residence and altered intratumoral distribution [30].